Skip to Accessibility Tools Skip to Content Skip to Footer

The Action for Chronic Migraine Treatment program sponsored

Pro Act

  1. Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599-609.
  2. Centers for Disease Control and Prevention. Census projections request. CDC WONDER website. Accessed June 13, 2013.
  3. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343-349.
  4. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71(8):559-566.
  5. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders: 3rd edition (beta version). Cephalalgia. 2013;33(9):629-808.
  6. Data on file, Allergan, Inc.; survey.
  7. Buse DC, Lipton RB. Facilitating communication with patients for improved migraine outcomes. Curr Pain Headache Rep. 2008;12(3):230-236.
  8. Holmes WF, MacGregor EA, Sawyer JPC, Lipton RB. Information about migraine disability influences physicians’ perceptions of illness severity and treatment needs. Headache. 2001;41(4):343-350.
  9. Silberstein SD; US Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(6):754-762.